Adagene Inc. has reported a net loss attributable to its shareholders of $13.5 million for the six months ended June 30, 2025, compared to a net loss of $17.0 million in the same period of 2024. The company noted a decrease in research and development expenses, which fell to $12.0 million from $14.7 million in the previous year, reflecting a strategic focus on their anti-CTLA-4 SAFEbody ADG126. Administrative expenses showed a slight increase, reaching $3.7 million from $3.6 million in the prior year. As of June 30, 2025, Adagene reported cash and cash equivalents of $62.8 million, a decrease from $85.2 million as of December 31, 2024. Additionally, total borrowings from commercial banks in China decreased significantly to $6.6 million from $18.2 million. In corporate updates, Adagene appointed John Maraganore, Ph.D. as Executive Advisor in April to aid in strategic guidance and growth. In May, Mickael Chane-Du joined as Chief Strategy Officer to enhance financing, strategic planning, and business development efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510990-en) on August 12, 2025, and is solely responsible for the information contained therein.
Comments